ResourceDrug Discovery & Development
Fragment screening of massively parallel ligand arrays using the Carterra Ultra SPR platform
3 Nov 2025Fragment-based lead discovery (FBLD) demands technologies that can detect low-affinity interactions across vast chemical space, posing throughput and sensitivity challenges. Discover how high-throughput surface plasmon resonance (SPR) innovations dramatically expand ligand capacity, streamline hit-to-lead workflows, and enable simultaneous analysis of over 100 targets, accelerating decision-making in early-stage drug discovery.
Related Products
Request Quote for All Products
Carterra Ultra™
CarterraDisruptive technology for the characterization of small molecules and fragments. With enhanced sensitivity, expanded thermal options, and advanced microfluidics, the Carterra Ultra™ platform is our most sensitive instrument for interrogating multiple proteins and off-target binding in parallel.